Thromb Haemost 2004; 92(06): 1273-1276
DOI: 10.1160/TH04-05-0268
Rapid and Short Communication
Schattauer GmbH

Genetic variation in Fcγ receptor IIa protects against advanced peripheral atherosclerosis

The Rotterdam Study
Irene M. van der Meer
1   Department of Epidemiology and Biostatistics, Erasmus Medical Center, Rotterdam, The Netherlands
,
Jacqueline C. M. Witteman
1   Department of Epidemiology and Biostatistics, Erasmus Medical Center, Rotterdam, The Netherlands
,
Albert Hofman
1   Department of Epidemiology and Biostatistics, Erasmus Medical Center, Rotterdam, The Netherlands
,
Cornelis Kluft
2   Gaubius Laboratory, TNO-Prevention and Health, Leiden, The Netherlands
,
Moniek P. M. de Maat
2   Gaubius Laboratory, TNO-Prevention and Health, Leiden, The Netherlands
› Author Affiliations
Financial support: Supported by the Netherlands Organization for Health Research and Development (ZON-MW), grant 980-10-005.
Further Information

Publication History

Received 02 May 2004

Accepted after revision 10 October 2004

Publication Date:
02 December 2017 (online)

Zoom Image

Summary

Immune processes play a substantial role in atherosclerotic disease. The role in atherosclerosis of Fcγ receptor IIa (FcγRIIa), a receptor for immunoglobulin G and for the inflammatory mediator C-reactive protein, is not yet clear. Since the R/H131 polymorphism in the FcγRIIa gene strongly influences binding to FcγRIIa, we investigated the association of the R/H131 polymorphism with advanced peripheral atherosclerosis. Within the Rotterdam Study, a population-based cohort study, we determined FcγRIIa genotype in 430 subjects with advanced peripheral atherosclerosis as indicated by the ankle-arm index, and 411 controls. Heterozygous and homozygous carriers of the H131 allele were protected against advanced peripheral atherosclerosis (age- and gender-adjusted odds ratio (OR) 0.77 (0.54–1.12) and 0.65 (0.44–0.98), respectively, P trend=0.04). This effect was most pronounced in subjects with modestly elevated levels of inflammation as indicated by the leukocyte count (OR 0.52 (0.29–0.93) and 0.45 (0.23–0.86), for heterozygotes and H131 homozygotes, respectively; P trend=0.02). This is the first study showing that the H131 allele of FcγRIIa protects against advanced peripheral atherosclerosis.